Promising cancer drugs targeting KRAS share data at AACR meeting in Orlando

ORLANDO – Two years after Amgen won approval for a drug going after one of cancer’s most frustrating genetic targets, researchers believe they’re finally beginning to scratch the surface of the class’ potential. The target, known as KRAS, is a protein regulating how cells grow and divide. Mutations can cause…